223 related articles for article (PubMed ID: 31595567)
1. Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis.
Bitaraf A; Babashah S; Garshasbi M
J Clin Lab Anal; 2020 Feb; 34(2):e23063. PubMed ID: 31595567
[TBL] [Abstract][Full Text] [Related]
2. Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues.
Mahmoudian M; Razmara E; Mahmud Hussen B; Simiyari M; Lotfizadeh N; Motaghed H; Khazraei Monfared A; Montazeri M; Babashah S
J Clin Lab Anal; 2021 Nov; 35(11):e24010. PubMed ID: 34528314
[TBL] [Abstract][Full Text] [Related]
3. Underexpression of circulating miR-145-5p and miR-133a-3p are associated with breast cancer and immunohistochemical markers.
García-Magallanes N; Beltran-Ontiveros SA; Leal-León EA; Luque-Ortega F; Romero-Quintana JG; Osuna-Ramirez I; Barbosa-Jasso M; Arámbula-Meraz E
J Cancer Res Ther; 2020; 16(6):1223-1228. PubMed ID: 33342777
[TBL] [Abstract][Full Text] [Related]
4. miR-125a-5p expression is associated with the age of breast cancer patients.
He H; Xu F; Huang W; Luo SY; Lin YT; Zhang GH; Du Q; Duan RH
Genet Mol Res; 2015 Dec; 14(4):17927-33. PubMed ID: 26782438
[TBL] [Abstract][Full Text] [Related]
5. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
6. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J
Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841
[TBL] [Abstract][Full Text] [Related]
7. A five-miRNA panel in plasma was identified for breast cancer diagnosis.
Li M; Zou X; Xia T; Wang T; Liu P; Zhou X; Wang S; Zhu W
Cancer Med; 2019 Nov; 8(16):7006-7017. PubMed ID: 31568692
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA profiling in serum: Potential signatures for breast cancer diagnosis.
Zou X; Xia T; Li M; Wang T; Liu P; Zhou X; Huang Z; Zhu W
Cancer Biomark; 2021; 30(1):41-53. PubMed ID: 32894240
[TBL] [Abstract][Full Text] [Related]
9. Analysis of miRNA-221 Expression Level in Tumors and Marginal Biopsies from Patients with Breast Cancer (Cross-Sectional Observational Study).
Abak A; Amini S; Estiar MA; Montazeri V; Sakhinia E; Abhari A
Clin Lab; 2018 Jan; 64(1):169-175. PubMed ID: 29479893
[TBL] [Abstract][Full Text] [Related]
10. A Signature of Four Circulating microRNAs as Potential Biomarkers for Diagnosing Early-Stage Breast Cancer.
Itani MM; Nassar FJ; Tfayli AH; Talhouk RS; Chamandi GK; Itani ARS; Makoukji J; Boustany RN; Hou L; Zgheib NK; Nasr RR
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204158
[TBL] [Abstract][Full Text] [Related]
11. Relationship of the Levels of microRNA Gene Methylation with the Level of Their Expression and Pathomorphological Characteristics of Breast Cancer.
Filippova EA; Pronina IV; Lukina SS; Kazubskaya TP; Braga EA; Burdennyi AM; Loginov VI
Bull Exp Biol Med; 2021 Oct; 171(6):764-769. PubMed ID: 34705180
[TBL] [Abstract][Full Text] [Related]
12. Plasma-based microRNA signatures in early diagnosis of breast cancer.
Li X; Zou W; Wang Y; Liao Z; Li L; Zhai Y; Zhang L; Gu S; Zhao X
Mol Genet Genomic Med; 2020 May; 8(5):e1092. PubMed ID: 32124558
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of miR-1245b-5p and miR-92a-3p and their potential target gene, GATA3, in epithelial-mesenchymal transition pathway in breast cancer.
Yadollahi Farsani M; Amini Farsani Z; Teimuri S; Kolahdouzan M; Eshraghi Samani R; Teimori H
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1955. PubMed ID: 38173189
[TBL] [Abstract][Full Text] [Related]
14. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
Zhang H; Zou X; Wu L; Zhang S; Wang T; Liu P; Zhu W; Zhu J
Cancer Med; 2020 Feb; 9(3):1230-1241. PubMed ID: 31856390
[TBL] [Abstract][Full Text] [Related]
15. A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis.
Zhang H; Zhu M; Shan X; Zhou X; Wang T; Zhang J; Tao J; Cheng W; Chen G; Li J; Liu P; Wang Q; Zhu W
Gene; 2019 Mar; 687():246-254. PubMed ID: 30458288
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of miR-143-3p and -424-5p in colorectal cancer and their clinical significance.
Sahami-Fard MH; Kheirandish S; Sheikhha MH
Cancer Biomark; 2019; 24(3):291-297. PubMed ID: 30883340
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients.
Fang C; Wang FB; Li Y; Zeng XT
Biomed Pharmacother; 2016 Dec; 84():1189-1193. PubMed ID: 27788476
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of oxidized low-density lipoprotein receptor 1 correlates with decreased miR-106b-5p, miR-93-5p, miR-3129-5p, miR-199b-3p, and miR-4465, higher recurrence rate, and poor prognosis in ovarian cancer.
Liu J; Zeng Y; Zheng L
Histol Histopathol; 2023 Apr; 38(4):475-485. PubMed ID: 36264049
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer.
Maleki E; Ghaedi K; Shahanipoor K; Karimi Kurdistani Z
APMIS; 2018 Apr; 126(4):303-308. PubMed ID: 29575198
[TBL] [Abstract][Full Text] [Related]
20. Human Papillomavirus 16 Oncoproteins Downregulate the Expression of miR-148a-3p, miR-190a-5p, and miR-199b-5p in Cervical Cancer.
Han MS; Lee JM; Kim SN; Kim JH; Kim HS
Biomed Res Int; 2018; 2018():1942867. PubMed ID: 30627542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
